Meeting
2014 ASCO Annual Meeting
Updated analysis of KRAS/NRAS and BRAF mutations in study 20050181 of panitumumab (pmab) plus FOLFIRI for second-line treatment (tx) of metastatic colorectal cancer (mCRC).
Authors
Marc Peeters
Antwerp University Hospital and University of Antwerp, Edegem, Belgium
Marc Peeters , Kelly Smith Oliner , Timothy Jay Price , Andres Cervantes , Alberto F. Sobrero , Michel Ducreux , Yevhen Hotko , Thierry Andre , Emily Chan , Florian Lordick , Cornelis J. A. Punt , Andrew Strickland , Gregory Wilson , Tudor E. Ciuleanu , Laslo Roman , Eric Van Cutsem , Hua Yu , Andre Scott Jung , Roger Sidhu , Scott D. Patterson
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Colorectal) Cancer
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Colorectal Cancer
Clinical Trial Registration Number
NCT00339183
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 3568)
DOI
10.1200/jco.2014.32.15_suppl.3568
Abstract #
3568
Poster Bd #
31
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
A randomized multicenter phase II study of FOLFIRI plus either panitumumab (Pmab) or bevacizumab (Bmab) as second-line treatment for wild-type KRAS exon 2 metastatic colorectal cancer (mCRC) with exploratory biomarker analysis by liquid biopsy: WJOG6210G.
First Author: Kohei Shitara
Poster
2017 Gastrointestinal Cancers Symposium
A phase Ib/II study of second-line therapy with panitumumab, irinotecan and everolimus (PIE) in metastatic colorectal cancer (mCRC) with KRAS wild type (WT): Biomarker substudy.
First Author: Amanda Rose Townsend
Poster
2016 ASCO Annual Meeting
Final results from a phase III trial evaluating panitumumab (pmab) + best supportive care (BSC) vs BSC in chemorefractory wild-type (WT) KRAS exon 2 and WT RAS metastatic colorectal cancer (mCRC).
First Author: Tae Won Kim
Poster
2016 Gastrointestinal Cancers Symposium
The prevalence RAS and BRAF mutations among patients in the Middle East and Northern Africa with metastatic colorectal cancer.
First Author: Tamer Garawin